Get the Stockscreener App
41.68
2.01%
0.82
Royalty Pharma Plc stock is traded at $41.68, with a volume of 3.47M.
It is up +2.01% in the last 24 hours and up +6.90% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$40.86
Open:
$41.27
24h Volume:
3.47M
Relative Volume:
0.88
Market Cap:
$17.81B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
23.83
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
+3.17%
1M Performance:
+6.90%
6M Performance:
+12.28%
1Y Performance:
+31.94%
1-Day Range:
$40.86
$41.72
1-Week Range:
$40.16
$41.72
52-Week Range:
$29.66
$41.72
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
41.68 | 17.46B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma stock hits 52-week high at $41.71 By Investing.com - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $41.71 - Investing.com
Royalty Pharma Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38 - marketscreener.com
Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma's (RPRX) Dividend Hike and Guidance Reset Change Its Efficiency and Growth Narrative - Sahm
(RPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer on Royalty Pharma: "It's a Terrific Company" - Finviz
84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC - MarketBeat
Jim Cramer on Royalty Pharma: “It’s a Terrific Company” - Insider Monkey
Jim Cramer Shared His Takes on These 16 Stocks - Insider Monkey
Baillie Gifford & Co. Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.7 million - Investing.com
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Smart Money: Is UAMY stock a buy or sellGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's - simplywall.st
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown - Yahoo Finance
Royalty Pharma (RPRX) Valuation Check After Recent Share Pullback And Strong 1 Year Return - Yahoo Finance
Patient Capital Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Dividend Hike Highlights Income Appeal And Undervaluation - Sahm
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock - MarketBeat
Royalty Pharma to announce fourth quarter and full year 2025 financial results on February 11, 2026 - marketscreener.com
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Globe and Mail
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Buys 207,338 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Latham Watkins Advises on Royalty Financing Agreement Between Teva and Royalty Pharma - Latham & Watkins LLP
Royalty Pharma announces planned legal leadership transition - MSN
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Aug Technicals: Will Royalty Pharma plc stock remain a Wall Street favoriteDollar Strength & High Win Rate Trade Alerts - moha.gov.vn
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com - Investing.com Canada
Urist Marshall, evp at Royalty Pharma, sells $815k in shares - Investing.com Australia
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing - marketscreener.com
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - Bộ Nội Vụ
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Jan 20 '26 |
Sale |
39.35 |
69,582 |
2,737,940 |
36,010 |
| Urist Marshall | EVP, Research & Investments |
Jan 16 '26 |
Sale |
39.52 |
20,000 |
790,346 |
40,000 |
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):